Business Update

CryoCath treats first patients with new SurgiFrost XL

Published in Medical Device Law Weekly, February 4th, 2007

CryoCath Technologies Inc., a global leader in cryotherapy products to treat cardiovascular disease, announced that the first patients have been treated with SurgiFrost XL, a new minimally invasive surgical probe for treating cardiac arrhythmias which the U.S. Food and Drug Administration provided 510(k) clearance for in late 2006.

It also received CE mark approval during this same time period.

"My experience with SurgiFrost XL in a preclinical setting confirms its ability to create durable, transmural lesions in a beating heart," said Dr. Saqib Masroor from Hackensack University Medical Center in Hackensack, New Jersey. "Given these results,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Law Weekly

Source: Medical Device Law Weekly (2007-02-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry